A month after sarcoma approval, Epizyme drug accepted for review as lymphoma treatment
The company said the FDA had accepted its application for accelerated approval of Tazverik in relapsed/refractory follicular lymphoma. The drug won accelerated approval last month for epithelioid sarcoma.